A process for making an intraocular implant, the process comprising the steps of: (a) combining: (i) a cyclic lipid therapeutic agent that is a prostaglandin, prostaglandin analog, prostaglandin derivative, prostamide, prostamide analog, or a prostamide derivative; (ii) a first biodegradable polymer selected from the group consisting of polylactic acid, polyglycolic acid, polylactide-co-glycolide, and copolymers thereof, and; (iii) a second biodegradable polymer selected from the group consisting of decafluorobutane, poly(isobutylene), poly(hexemethylene adipamide), poly propylene, poly ethylene and polyethylene glycol to form a mixture, wherein; (β) the solubilities of the cyclic lipid therapeutic agent, the first biodegradable polymer, and the second biodegradable polymer are all within 10 Mpa 1⁄2 of each other, and; (γ) the melt temperature of the second biodegradable polymer is lower than the melt transition temperature of the first biodegradable polymer, (b) heating the mixture to the lower melt temperature of the second biodegradable polymer, so that the second biodegradable polymer can function as a solvent for the cyclic lipid therapeutic agent and for the first biodegradable polymer, wherein the melt temperature of the second biodegradable polymer is lower than the temperature at which the cyclic lipid therapeutic agent loses 50% or more of its potency, and; (c) extruding the heated mixture, thereby making an implant suitable for intraocular use. (a) combining: (i) a cyclic lipid therapeutic agent that is a prostaglandin, prostaglandin analog, prostaglandin derivative, prostamide, prostamide analog, or a prostamide derivative; (ii) a first biodegradable polymer selected from the group consisting of polylactic acid, polyglycolic acid, polylactide-co-glycolide, and copolymers thereof, and; (iii) a second biodegradable polymer selected from the group consisting of decafluorobutane, poly(isobutylene), poly(hexemethylene adipamide), poly propylene, poly ethylene and polyethylene glycol to form a mixture, wherein; (β) the solubilities of the cyclic lipid therapeutic agent, the first biodegradable polymer, and the second biodegradable polymer are all within 10 Mpa 1⁄2 of each other, and; (γ) the melt temperature of the second biodegradable polymer is lower than the melt transition temperature of the first biodegradable polymer, (i) a cyclic lipid therapeutic agent that is a prostaglandin, prostaglandin analog, prostaglandin derivative, prostamide, prostamide analog, or a prostamide derivative; (ii) a first biodegradable polymer selected from the group consisting of polylactic acid, polyglycolic acid, polylactide-co-glycolide, and copolymers thereof, and; (iii) a second biodegradable polymer selected from the group consisting of decafluorobutane, poly(isobutylene), poly(hexemethylene adipamide), poly propylene, poly ethylene and polyethylene glycol to form a mixture, wherein; (β) the solubilities of the cyclic lipid therapeutic agent, the first biodegradable polymer, and the second biodegradable polymer are all within 10 Mpa 1⁄2 of each other, and; (γ) the melt temperature of the second biodegradable polymer is lower than the melt transition temperature of the first biodegradable polymer, (β) the solubilities of the cyclic lipid therapeutic agent, the first biodegradable polymer, and the second biodegradable polymer are all within 10 Mpa 1⁄2 of each other, and; (γ) the melt temperature of the second biodegradable polymer is lower than the melt transition temperature of the first biodegradable polymer, (b) heating the mixture to the lower melt temperature of the second biodegradable polymer, so that the second biodegradable polymer can function as a solvent for the cyclic lipid therapeutic agent and for the first biodegradable polymer, wherein the melt temperature of the second biodegradable polymer is lower than the temperature at which the cyclic lipid therapeutic agent loses 50% or more of its potency, and; (c) extruding the heated mixture, thereby making an implant suitable for intraocular use.